/content/mofsl-website-adobe/fragments/open-demat-popup

style

hide-in-desktop

Alterity Therapeutics Ltd share price today is $3.55, up -0.56%. The stock opened at $3.47 against the previous close of $3.57, with an intraday high of $3.47 and low of $3.47.

style

pb-0

Alterity Therapeutics Ltd

/content/mofsl-website-adobe/demat-form-fields

style

sticky-block,pt-0

us-stock

style

pt-0

$3.55 -0.0056(-0.56%) ATHE at 13 Mar 2026 12:04 PM Biotechnology

Lowest Today 3.47

Highest Today 3.47

Today’s Open 3.47

Prev. Close 3.57

52 Week High 7.00

52 Week Low 2.52

Day’s Range: Low 3.47 High 3.47

52-Week Range: Low 2.52 High 7.00

Alterity Therapeutics Ltd Institutional Holdings

Alterity Therapeutics Ltd Market Status

Strong Buy: 1

Buy: 1

Hold: 1

Sell: 0

Strong Sell: 0

Alterity Therapeutics Ltd Fundamentals

Market Cap 67.51 M

PB Ratio 1.6872

PE Ratio 0.0

Enterprise Value 26.79 M

Total Assets 46.03 M

Volume 2361

Alterity Therapeutics Ltd Company Financials

Annual Revenue FY25:5438918 5.4M, FY24:4019285 4.0M, FY23:0 0.0M, FY22:3537368 3.5M, FY21:3254048 3.3M

Annual Profit FY25:5311395 5.3M, FY24:3804981 3.8M, FY23:null 0.0M, FY22:3285598 3.3M, FY21:2984083 3.0M

Annual Net worth FY25:-12147828 -12.1M, FY24:-19123464 -19.1M, FY23:-13806515 -13.8M, FY22:-12847061 -12.8M, FY21:-15309353 -15.3M

Quarterly Revenue Q2/2025:3832993 3.8M, Q2/2024:2118561 2.1M, Q1/2024:690715 0.7M, Q2/2023:null 0.0M, Q1/2023:null 0.0M

Quarterly Profit Q2/2025:3769068 3.8M, Q2/2024:2044949 2.0M, Q1/2024:652460 0.7M, Q2/2023:null 0.0M, Q1/2023:null 0.0M

Quarterly Net worth Q2/2025:-4974493 -5.0M, Q2/2024:-12616281 -12.6M, Q1/2024:-4113288 -4.1M, Q2/2023:null 0.0M, Q1/2023:null 0.0M

About Alterity Therapeutics Ltd & investment objective

Company Information Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.

Organisation Biotechnology

Employees 9

Industry Biotechnology

CEO Dr. David A. Stamler M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*